Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has announced a significant policy change requiring all new vaccines to undergo placebo-controlled trials before they are licensed. This move, described by an HHS spokesperson as a "radical departure from past practices," aims to enhance the safety testing protocols for vaccines, particularly those recommended for children by the Centers for Disease Control and Prevention (CDC).
The spokesperson pointed out that, aside from the COVID-19 vaccine, existing vaccines on the CDC's childhood schedule have not been tested against inert placebos, raising concerns about the understanding of their risk profiles. Placebo-controlled trials typically involve administering saline shots or dummy injections to a portion of volunteers, a method commonly used for new vaccines targeting emerging pathogens. However, updated versions of established vaccines often bypass these trials, being compared instead to existing vaccines.
Some health experts have expressed concerns regarding the ethical implications of conducting placebo trials, especially in cases where effective vaccines are already available. A 2014 report from the World Health Organization acknowledged that using a placebo can pose ethical challenges, but noted that such trials may be justified under certain conditions.
The HHS also criticized the CDC's current monitoring systems for vaccine complications, claiming that they do not effectively capture adverse events. It stated that the Vaccine Adverse Event Reporting System (VAERS) records fewer than 1% of vaccine injuries, while the Vaccine Safety Datalink (VSD) is described as inadequate for serious research.
Kennedy has emphasized the importance of transparency in the vaccine testing and approval process, asserting that the HHS is committed to providing clear information about the safety and effectiveness of vaccines.